Home > Journals > Minerva Urologica e Nefrologica > Past Issues > Minerva Urologica e Nefrologica 2000 September;52(3) > Minerva Urologica e Nefrologica 2000 September;52(3):123-5

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

MINERVA UROLOGICA E NEFROLOGICA

A Journal on Nephrology and Urology


Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,536


eTOC

 

  XVI CONGRESS DELLA SOCIETÀ ITALIANA DI NEFROLOGIA SEZIONE PIEMONTE-VALLE D’AOSTA
Castello di Rivoli, Rivoli (TO) October 10, 1998


Minerva Urologica e Nefrologica 2000 September;52(3):123-5

language: Italian

Acute renal failure and losartan: a recently observed event with angiotensin II receptor antagonists

Dionisio P., Valenti M., Caramello E., Bergia R., Cravero R., Berto I. M., Agostini B., Monaci G., Bajardi P.

Ospedale degli Infermi - Biella Servizio di Nefrologia e Dialisi


PDF  


Losartan is the first of a new cathegory of drug that inhibits angiotensin II (ANG II) AT1 receptors antagonists. This drug lowers blood pressure by inhibiting the activity of ANG II and reduces proteinuria and progression of chronic renal failure (CRF). It seems therefore an extremely interesting drug. Aim of this study is to describe 3 cases of acute renal failure (ARF), occurred during therapy with losartan. None of the patients showed renal arteries stenosis or other predisposing factors for the development of ARF. In conclusion, we want pointed out that losartan could affect renal function in a similar way as angiotensin converting enzyme inhibitors (ACEI). We suggested that the use of losartan in risk situations, like old age, preexiting CRF, stenosis of renal arteries, soliary kidney and diuretic therapy, should be carefully monitored as well as that of ACEI.

top of page

Publication History

Cite this article as

Corresponding author e-mail